Klinik für Urologie und Kinderurologie

Studien zur überaktiven Blase und Harnblasenkarzinom

CA045-009

A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier

A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier. 

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally ated Locally Advanced or Metastatic Urothelial Cancer

Studien-Status: geschlossen

Weitere Informationen finden Sie hier. 

A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier. 

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer

Studien-Status: geöffnet

Weitere Informationen finden Sie hier. 

A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Studien-Status: geschlossen

Weitere Informationen finden Sie hier.

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

Studien-Status: geöffnet

Weitere Informationen finden Sie hier.

A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

Studien-Status: geschlossen

Weitere Informationen finden Sie hier. 

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)

Studien-Status: wird geöffnet

Weitere Informationen finden Sie hier.

 
 
 
 

Kontakt

Barbara Thielen (Ltd. study nurse)
Ansgar Nehus (study nurse)
Michael Grenzebach (study nurse)
Anika Kunz (study nurse)

Terminvereinbarung
Montag bis Freitag: 10 - 15 Uhr
E uroonkologie@ukmuenster.de
T +49 (0)251- 83 48 12 6

IN NOTFÄLLEN
T +49 (0)251- 83 47 44 6 oder
T +49 (0)251- 83 48 00 1